Getz Healthcare Partners with Subtle Medical to Improve Medical Imaging with AI-powered Technology

Getz Healthcare Pty Ltd announced today that they have partnered with Subtle Medical, a U.S-based healthcare technology company, to distribute the company’s artificial intelligence (AI)-based software solutions for faster and safer medical imaging. Subtle’s solutions could provide significant efficiency gains for hospitals and private radiology clinics within Australia and New Zealand, resulting in more timely patient access to critical PET and MRI imaging services.

Subtle Medical’s software solution, SubtlePET™, uses proprietary deep learning algorithms to denoise low count PET images from up to 75% lower radiotracer dose and faster scan times. SubtleMR™ uses increased sharpness and denoising to improve the image quality on up to 60% faster MRI exams. The solutions result in a broad range of benefits including faster scan times, lower radiation dose, improved image quality, higher scanner efficiency, and positive impacts on workflow and patient experience. Subtle’s solutions are compatible across all PET and MRI scanner brands, makes, and models, and seamlessly integrate into existing workflows.

“We are thrilled to be expanding patient access to our AI solutions. Our goal is to not only make medical imaging safer and more focused on the patient, but also help imaging institutions and radiologists achieve higher-quality imaging while running a more efficient operation. We are looking forward to a productive partnership with Getz,” said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

James Simkins, CEO, Getz Healthcare, added, “We are really excited to be partnering with Subtle Medical. We believe Subtle Medical’s software solution will bring tangible benefits to our customers and ultimately patients.” “The possibility for Subtle Medical’s software solutions to improve efficiency and image quality while extending the life of existing imaging systems is a real game changer for radiologists and patients in need of access to imaging. We are delighted to introduce this technology to Australia and New Zealand,” said Kimberly Hill, Managing Director of Getz Healthcare Australia & New Zealand.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy